IGC20: Statement by the Holy See on patenting of life forms
Statement by the Permanent Mission of the Holy See to the United Nations and Other International Organizations in Geneva at the World Intellectual Property Organization (WIPO)- Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore (IGC)
Geneva, 17 February 2012
Mr. President,I join previous speakers and congratulate you on your election.
UPDATE: WIPO intergovernmental committee debates patents on life in relation to IP and genetic resources
18 January 2012
Chair of IGC 20, Ambassador Wayne McCook, Jamaica, and Wend Wendland, WIPO
Courtesy of Marc PerlmanUSPTO Holds Public Hearing on Genetic Diagnostic Testing
On February 16, 2012, the USPTO held a public hearing on genetic diagnostic testing, permitting stakeholders to present their views relating to DNA patents, exclusive licensing, patient health and genetic testing, particularly as they relate to secondary or confirmatory genetic diagnostic testing. Notes from the hearing and speaker statements are included below. KEI’s oral statement can be found here.
KEI Statement at USPTO Public Hearing on Genetic Diagnostic Testing
On February 16, 2012, the USPTO held a public hearing on genetic diagnostic testing, pursuant to a Congressional mandate that was part of the America Invents Act. This mandate directed the USPTO to evaluate several questions related to genetic diagnostic testing, particularly with regard to second opinion or confirmatory genetic testing. USPTO will deliver its final report to Congress in June. Notes from the public hearing are available in a separate blog post.
Who USTR clears to see secret text for IPR negotiations? (Such as TPPA)
In a meeting with USTR on February 15, 2012, KEI, MSF, Oxfam and Public Citizen pressed USTR to release the negotiating text for the intellectual property rights chapter in the TPPA trade agreement negotiation. USTR said the negotiation had “unprecedented” transparency, but maintained the text needed to be secret from the general public. USTR also claimed than no one on its many advisory boards, who are cleared to see the negotiating text, were lobbyists.
What we don’t know, and why, about incentives to stimulate biomedical R&D
This is an essay about strategic ignorance, as regards evidence relevant to policies that cost consumers and taxpayers billions of dollars.
The United States government grants 20 year patents on pharmaceutical drugs, and it also provides a growing number of other non-patent incentives and subsidies to stimulate R&D investments in new medicines. Are these incentives and subsidies necessary or cost effective? How would anyone know?
Here are some of the incentives we offer:
- Up to five year extensions of patents on pharmaceutical drugs.
February 22 noon Washington, DC meeting to discuss international negotiations on copyright (With international call-in)
On Wednesday February 22, 2012, from 12:30pm to 2:30pm, KEI will host a roundtable discussion on international copyright negotiations. The location of the meeting will be 1621 Connecticut Ave, NW, Suite 500, Washington, DC 20009. There will be an opportunity to participate by telephone, via toll free calls in many countries. (To register or for details on call-in, email manon.ress@keionline.org. If you want to try to join by skype, we will do our best.)
The topics to be discussed are the following International copyright negotiations:
KEI files affidavit in India compulsory licensing case involving Bayer patents on cancer drug Sorafenib (Nexavar)
KEI has provided an affidavit in an India compulsory licensing dispute involving Natco and Bayer, for patents on the cancer drug sorafenib (sold by Bayer under the brand name Nexavar).
The Bayer price for sorafenib/Nexavar in India is $47 per 200 milligram tablet. At a daily dose of 4 tablets, this comes to $5,637 per month, or more than $68 thousand per year. In 2010, per capita income in India was $1,330.
NGO views on the Africa IP Summit
Sangeeta Shashikant from TWN recently collected and published several NGO statements on the Africa IP Summit, in the TWO Info Service on Intellectual Property Issues (Feb12/03), which included a link also to a letter to WIPO signed by more than 100 NGOs. Continue Reading
KEI and Essential Inventions comments to Special 301 Committee